India, Feb. 24 -- BioCryst Pharmaceuticals, Inc. (BCRX) Monday reported positive results from APeX-P study of Orladeyo in hereditary angioedema (HAE) patients aged between 2 and 12 years.
APeX-P study is designed to evaluate oral formulation of Orladeyo to prevent HAE in patients aged 2 to less than 12 years old. Interim data from the study showed that treatment with Orladeyo demonstrated early and sustained reductions in monthly HAE attack rates. Further, the drug was found to be safe and well tolerated.
The company said it is on track to submit New Drug Application to the Food and Drug Administration (FDA) this year.
Orladeyo is already approved by the FDA to prevent attacks of HAE in individuals aged 12 years and older.
For comments ...